NCT05706233

Brief Summary

Laparoscopic cholecystectomy, one of the most commonly performed abdominal surgeries, is a gold standard therapy for surgical treatment of benign biliary diseases. Erector spinae plane block (ESPB) was first presented in 2016 as the treatment of neuropathic pain in a case series, and gained popularity very quickly due to its safety applicability, and effect on both the visceral and parietal component of pain by providing paravertebral, transforaminal and epidural spread. Preoperative application of ESPB has taken its place as a part of multimodal analgesia in laparoscopic cholecystectomy cases over time and has been shown to reduce postoperative pain scores and opioid consumption and to improve quality of recovery scores. However, there is no data regarding the use of ESPB in the postoperative period as a rescue therapy.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
108

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Feb 2022

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 15, 2022

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 15, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 15, 2022

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

January 9, 2023

Completed
22 days until next milestone

First Posted

Study publicly available on registry

January 31, 2023

Completed
Last Updated

June 28, 2023

Status Verified

June 1, 2023

Enrollment Period

3 months

First QC Date

January 9, 2023

Last Update Submit

June 27, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • effect of ESPB applied postoperatively on the meperidine consumption in PACU

    As part of the standardized perioperative care management, the pain intensity is evaluated with the numeric pain rating scale (NRS). If the NRS is \> 3 meperidine bolus or ESPB is applied in line with the patients' selection and the patients are evaluated in every 5 min in terms of their NRS scores until NRS \< 4 is achieved. If NRS score is not reduced at least 20% when compared to prior one, additional meperidine bolus is applied. All meperidine boluses are dosed in line with the pain intensity as follows: 10 mg if NRS \> 3, 20 mg if NRS \> 5, 30 mg if NRS \> 8. NRS scores and meperidine boluses applied are recorded on the PACU follow-up form.

    1 HOUR

Secondary Outcomes (1)

  • effect of ESPB applied postoperatively on numeric rating scores in PACU

    1 HOUR

Study Arms (2)

Erector Spina Plane Block (ESPB)

Procedure: Erector Spina Plane Group

Intravenous Group (IV)

Procedure: IV analgesic intervention

Interventions

ESPB had been applied postoperatively: from T8 level, 20mL bupivacaine %0,5 + 5ml %2 lidocaine was applied.

Erector Spina Plane Block (ESPB)

IV analgesics had been applied: All meperidine boluses are dosed in line with the pain intensity as follows: 10 mg if NRS \> 3, 20 mg if NRS \> 5, 30 mg if NRS \> 8. If NRS score is not reduced at least 20% when compared to prior one, additional meperidine bolus is applied.

Intravenous Group (IV)

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients undergoing laparoscopic cholecystectomy

You may qualify if:

  • Patients undergoing laparoscopic cholecystectomy
  • Patients with NRS\>3 scores in the PACU

You may not qualify if:

  • ASA \> 2
  • Violation of standart protocol (anesthesia and analgesia)
  • application of ESPB preoperatively
  • age \> 65
  • Surgery duration \>90min or \<45min

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Istanbul Basaksehir Cam and Sakura City Hospital

Istanbul, Turkey (Türkiye)

Location

MeSH Terms

Conditions

CholecystitisBronchiolitis Obliterans Syndrome

Condition Hierarchy (Ancestors)

Gallbladder DiseasesBiliary Tract DiseasesDigestive System DiseasesOrganizing PneumoniaBronchiolitis ObliteransBronchiolitisBronchitisBronchial DiseasesRespiratory Tract DiseasesLung Diseases, ObstructiveLung DiseasesGraft vs Host DiseaseImmune System Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Specialist

Study Record Dates

First Submitted

January 9, 2023

First Posted

January 31, 2023

Study Start

February 15, 2022

Primary Completion

May 15, 2022

Study Completion

May 15, 2022

Last Updated

June 28, 2023

Record last verified: 2023-06

Data Sharing

IPD Sharing
Will share

Locations